- Home
- EYPT vs RSI Comparison
EYPT vs RSI Comparison
Compare EYPT & RSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EYPT | RSI |
|---|---|---|
| Founded | 1987 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Services-Misc. Amusement & Recreation |
| Sector | Industrials | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.8B |
| IPO Year | 2005 | 2020 |
Fundamental Metrics
Financial Performance| Metric | EYPT | RSI |
|---|---|---|
| Price | $18.29 | $20.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $28.75 | $22.75 |
| AVG Volume (30 Days) | 1.6M | ★ 2.5M |
| Earning Date | 03-23-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 933.33 |
| EPS | N/A | ★ 0.31 |
| Revenue | $7,539,000.00 | ★ $1,134,428,000.00 |
| Revenue This Year | N/A | $17.42 |
| Revenue Next Year | N/A | $14.26 |
| P/E Ratio | ★ N/A | $63.76 |
| Revenue Growth | N/A | ★ 22.76 |
| 52 Week Low | $3.91 | $9.54 |
| 52 Week High | $19.11 | $22.65 |
Technical Indicators
Market Signals| Indicator | EYPT | RSI |
|---|---|---|
| Relative Strength Index (RSI) | 67.28 | 64.97 |
| Support Level | $11.88 | $16.41 |
| Resistance Level | $19.06 | $20.14 |
| Average True Range (ATR) | 1.27 | 0.97 |
| MACD | 0.54 | 0.34 |
| Stochastic Oscillator | 90.58 | 92.23 |
Price Performance
Historical ComparisonAbout EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
About RSI Rush Street Interactive Inc.
Rush Street Interactive Inc is an online gaming and entertainment company that focuses on online casinos and online sports betting in the U.S. and Latin American markets. It provides customers with an array of gaming offerings such as real-money online casinos, online sports betting, and retail sports betting, as well as social gaming, which involves free-to-play games that use virtual credits that can be earned or purchased. The company generates revenue by offering online casinos, online sports betting, and social gaming directly to the end customer through its websites or apps. The company generates revenue through business-to-consumer (B2C) and business-to-business (B2B) models.